The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin

Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder

(2020) Yves Dauvilliers et al.   ANNALS OF NEUROLOGY

Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder

(2020) Gary Zammit et al.   NEUROLOGY

Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration

(2019) Clemens Muehlan et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study

(2018) Clemens Muehlan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies

(2018) Marie-Laure Boof et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468

(2017) Alexander Treiber et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives

(2016) Yuzhuo Pan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies

(2016) P. Martin et al.   Drugs in research & development

Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update

(2014) Qingcheng Mao et al.   AAPS Journal

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY